Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Assets Average (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Assets Average for 7 consecutive years, with $427.8 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 24.8% to $427.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $427.8 million through Dec 2025, down 24.8% year-over-year, with the annual reading at $482.3 million for FY2025, 19.05% down from the prior year.
  • Assets Average hit $427.8 million in Q4 2025 for Allogene Therapeutics, down from $455.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.2 billion in Q1 2021 to a low of $427.8 million in Q4 2025.
  • Historically, Assets Average has averaged $778.8 million across 5 years, with a median of $752.4 million in 2023.
  • Biggest five-year swings in Assets Average: soared 71.15% in 2021 and later dropped 26.35% in 2025.
  • Year by year, Assets Average stood at $1.1 billion in 2021, then decreased by 19.44% to $858.0 million in 2022, then fell by 20.97% to $678.1 million in 2023, then fell by 16.1% to $568.9 million in 2024, then fell by 24.8% to $427.8 million in 2025.
  • Business Quant data shows Assets Average for ALLO at $427.8 million in Q4 2025, $455.2 million in Q3 2025, and $489.3 million in Q2 2025.